## VPA10983/040/001

## Oridermyl ear gel

Variation	Summary	Date
	VNRA - Vet - B37 Vet - B37 - Change in shape or	
Vet - B37	dimensions of the container or closure (immediate	16/12/25
	packaging) of a non-sterile finished product	
	VNRA - Vet - B44 - Submission of a new or updated Ph.	24/03/25
	Eur. CEP from an already approved manufacturer for a	
Vet - B44(Do not use)	non-sterile active substance, starting material, reagent or	
	intermediate, excipient - B44 Changes to the quality part	
	of the dossier: Submission of a new or updated Ph. Eur.	
	CEP from an already approved manufacturer for a	
	non-sterile: — active substance; — starting material,	
	reagent or intermediate used in the manufacturing process	
	of the active substance; — excipient	
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product	22/11/24
	information with version 9.0 (or the latest version of the	
	QRD templates that are in effect at the time that this	
	one-off variation is submitted) of the QRD templates i.e.	
	major update of the QRD templates in accordance with	
	Regulation (EU) 2019/6, for veterinary medicinal	
	products placed on the market in accordance with	
	Directive 2001/82/EC or Regulation (EC) No 726/2004 -	
	G.I.18 Safety, Efficacy, Pharmacovigilance changes -	
	One-off alignment of the product information with	
	version 9.0 (or the latest version of the QRD templates	
	that are in effect at the time that this one-off variation is	
	submitted) of the QRD templates i.e. major update of the	
	QRD templates in accordance with Regulation (EU)	
	2019/6, for veterinary medicinal products placed on the	
	market in accordance with Directive 2001/82/EC or	
	Regulation (EC) No 726/2004	
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph.	
	Eur. CEP from an already approved manufacturer for a	30/06/23
	non-sterile active substance, starting material, reagent or	
	intermediate, excipient - B44 Changes to the quality part	
	of the dossier: Submission of a new or updated Ph. Eur.	
	CEP from an already approved manufacturer for a	
	non-sterile: — active substance; — starting material,	
	reagent or intermediate used in the manufacturing process	
	of the active substance; — excipient	
	VNRA - Vet - B44 - Submission of a new or updated Ph.	
Vet - B44(Do not use)	Eur. CEP from an already approved manufacturer for a	
	non-sterile active substance, starting material, reagent or	09/06/23
	intermediate, excipient - B44 Changes to the quality part	
	of the dossier: Submission of a new or updated Ph. Eur.	
	CEP from an already approved manufacturer for a	L

	non-sterile: — active substance; — starting material,	
	reagent or intermediate used in the manufacturing process	
	of the active substance; — excipient	
Vet - F.III.2 z)	VRA-R - Vet - F.III.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.2 z) Quality Changes - CEP/TSE/MONOGRAPHS - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other changes under this code level, e.g. variations	18/05/23
	outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	18/05/23
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	31/03/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	31/03/23